These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37093546)

  • 1. Multi-omic profiling reveals an RNA processing rheostat that predisposes to prostate cancer.
    Stentenbach M; Ermer JA; Rudler DL; Perks KL; Raven SA; Lee RG; McCubbin T; Marcellin E; Siira SJ; Rackham O; Filipovska A
    EMBO Mol Med; 2023 Jun; 15(6):e17463. PubMed ID: 37093546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in ELAC2 associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3'-end processing.
    Saoura M; Powell CA; Kopajtich R; Alahmad A; Al-Balool HH; Albash B; Alfadhel M; Alston CL; Bertini E; Bonnen PE; Bratkovic D; Carrozzo R; Donati MA; Di Nottia M; Ghezzi D; Goldstein A; Haan E; Horvath R; Hughes J; Invernizzi F; Lamantea E; Lucas B; Pinnock KG; Pujantell M; Rahman S; Rebelo-Guiomar P; Santra S; Verrigni D; McFarland R; Prokisch H; Taylor RW; Levinger L; Minczuk M
    Hum Mutat; 2019 Oct; 40(10):1731-1748. PubMed ID: 31045291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2.
    Dumont M; Frank D; Moisan AM; Tranchant M; Soucy P; Breton R; Labrie F; Tavtigian SV; Simard J
    Biochim Biophys Acta; 2004 Sep; 1679(3):230-47. PubMed ID: 15358515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of TRZ1, a yeast homolog of the human candidate prostate cancer susceptibility gene ELAC2 encoding tRNase Z.
    Chen Y; Beck A; Davenport C; Chen Y; Shattuck D; Tavtigian SV
    BMC Mol Biol; 2005 May; 6():12. PubMed ID: 15892892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease.
    Takaku H; Minagawa A; Takagi M; Nashimoto M
    Nucleic Acids Res; 2003 May; 31(9):2272-8. PubMed ID: 12711671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.
    Traoré ADD; Ky BD; Traoré L; Zohoncon TM; Zouré AA; Yonli AT; Sombié HK; Sorgho PA; Elvira Bazié BVJT; Tovo SFA; Kadanga E; Bakyono BS; Traore K; Ouédraogo TC; Djigma FW; Simpore J
    Prostate Cancer; 2022; 2022():3610089. PubMed ID: 36643816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of HPC2/ELAC2 in hereditary prostate cancer.
    Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.
    Xu J; Zheng SL; Carpten JD; Nupponen NN; Robbins CM; Mestre J; Moses TY; Faith DA; Kelly BD; Isaacs SD; Wiley KE; Ewing CM; Bujnovszky P; Chang B; Bailey-Wilson J; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB
    Am J Hum Genet; 2001 Apr; 68(4):901-11. PubMed ID: 11254448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.
    Chen YC; Giovannucci E; Kraft P; J Hunter D
    Carcinogenesis; 2008 May; 29(5):999-1004. PubMed ID: 18375959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.
    Noda D; Itoh S; Watanabe Y; Inamitsu M; Dennler S; Itoh F; Koike S; Danielpour D; ten Dijke P; Kato M
    Oncogene; 2006 Sep; 25(41):5591-600. PubMed ID: 16636667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.
    Schroeder C; Navid-Hill E; Meiners J; Hube-Magg C; Kluth M; Makrypidi-Fraune G; Simon R; Büscheck F; Luebke AM; Goebel C; Lang DS; Weidemann S; Neubauer E; Hinsch A; Jacobsen F; Lebok P; Michl U; Pehrke D; Huland H; Graefen M; Schlomm T; Sauter G; Höflmayer D
    Oncotarget; 2019 Aug; 10(48):4973-4986. PubMed ID: 31452838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common genetic variant of a mitochondrial RNA processing enzyme predisposes to insulin resistance.
    Rossetti G; Ermer JA; Stentenbach M; Siira SJ; Richman TR; Milenkovic D; Perks KL; Hughes LA; Jamieson E; Xiafukaiti G; Ward NC; Takahashi S; Gray N; Viola HM; Hool LC; Rackham O; Filipovska A
    Sci Adv; 2021 Sep; 7(39):eabi7514. PubMed ID: 34559558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.
    Alvarez-Cubero MJ; Pascual-Geler M; Martinez-Gonzalez LJ; Expósito Ruiz M; Saiz M; Cozar JM; Lorente JA
    Urol Oncol; 2016 Oct; 34(10):431.e1-8. PubMed ID: 27318894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon.
    Djomkam ALZ; Beyeme Sala T; Baari Memba C; Njimoh DL
    Prostate Cancer; 2019; 2019():5974928. PubMed ID: 31321101
    [No Abstract]   [Full Text] [Related]  

  • 15. Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer.
    Camp NJ; Tavtigian SV
    Am J Hum Genet; 2002 Dec; 71(6):1475-8. PubMed ID: 12515253
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
    Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
    Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
    Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
    J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
    Thompson VC; Day TK; Bianco-Miotto T; Selth LA; Han G; Thomas M; Buchanan G; Scher HI; Nelson CC; ; Greenberg NM; Butler LM; Tilley WD
    Int J Cancer; 2012 Aug; 131(3):662-72. PubMed ID: 22275114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy.
    Haack TB; Kopajtich R; Freisinger P; Wieland T; Rorbach J; Nicholls TJ; Baruffini E; Walther A; Danhauser K; Zimmermann FA; Husain RA; Schum J; Mundy H; Ferrero I; Strom TM; Meitinger T; Taylor RW; Minczuk M; Mayr JA; Prokisch H
    Am J Hum Genet; 2013 Aug; 93(2):211-23. PubMed ID: 23849775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.
    Nupponen NN; Wallén MJ; Ponciano D; Robbins CM; Tammela TL; Vessella RL; Carpten JD; Visakorpi T
    Genes Chromosomes Cancer; 2004 Feb; 39(2):119-25. PubMed ID: 14695991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.